We are live on ! Find out more
GNMX

Aevi Genomic Medicine Inc
GNMX

Delisted

GNMX was delisted on the 3rd of February, 2020.

Back to rankings

38 hedge funds and large institutions have $8.64M invested in Aevi Genomic Medicine Inc in 2018 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 10 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

14% less funds holding

Funds holding: 44 → 38 (-6)

30% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 10

45% less capital invested

Capital invested by funds: $15.6M → $8.64M (-$6.98M)

75% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 8

Holders
38
Holders Change
-6
Holders Change %
-13.64%
% of All Funds
0.85%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
2
Increased
7
Reduced
10
Closed
8
Calls
$4K
Puts
–
Net Calls
+$4K
Net Calls Change
-$66K

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$40.3K
2
VF
Virtu Financial
New York
+$25.5K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$24.4K
4
Jane Street
Jane Street
New York
+$13.5K
5
Morgan Stanley
Morgan Stanley
New York
+$3.7K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$291K
2
Millennium Management
Millennium Management
New York
-$61.4K
3
PAM
Panagora Asset Management
Massachusetts
-$45K
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$45K
5
Goldman Sachs
Goldman Sachs
New York
-$38K
Name Holding Trade Value Shares
Change 		Change in
Stake
Adage Capital Partners
1
Adage Capital Partners
Massachusetts
$3.85M – – –
BBA
2
Baker Bros. Advisors
New York
$2.77M – – –
BlackRock
3
BlackRock
New York
$548K +$1.12K +1,002 +0.1%
Vanguard Group
4
Vanguard Group
Pennsylvania
$508K -$291K -260,797 -26%
BCM
5
Bridgeway Capital Management
Texas
$156K – – –
WS
6
Wedbush Securities
California
$141K – – –
Geode Capital Management
7
Geode Capital Management
Massachusetts
$117K – – –
Wells Fargo
8
Wells Fargo
California
$91K -$670 -600 -0.5%
BC
9
Birchview Capital
Vermont
$90K – – –
Renaissance Technologies
10
Renaissance Technologies
New York
$45K +$40.3K +36,107 +126%
Millennium Management
11
Millennium Management
New York
$43K -$61.4K -54,976 -47%
AMCA
12
Arthur M. Cohen & Associates
Illinois
$38.6K – – –
California Public Employees Retirement System
13
California Public Employees Retirement System
California
$36K – – –
Northern Trust
14
Northern Trust
Illinois
$35K – – –
VF
15
Virtu Financial
New York
$25K +$25.5K +22,849 +174%
Susquehanna International Group
16
Susquehanna International Group
Pennsylvania
$23K +$24.4K +21,806 +194%
Bank of New York Mellon
17
Bank of New York Mellon
New York
$20K – – –
PAM
18
Panagora Asset Management
Massachusetts
$14K -$45K -40,316 -67%
Acadian Asset Management
19
Acadian Asset Management
Massachusetts
$14K – – –
State Street
20
State Street
Massachusetts
$12K – – –
VAM
21
Verity Asset Management
North Carolina
$12K +$3.35K +3,000 +21%
Citadel Advisors
22
Citadel Advisors
Florida
$11K -$1.14K -1,022 -6%
OIA
23
OneDigital Investment Advisors
Kansas
$11K -$147 -132 -0.8%
Jane Street
24
Jane Street
New York
$8K +$13.5K +12,102 New
MWP
25
MYCIO Wealth Partners
Pennsylvania
$7K – – –
1
2

GNMX Hedge Fund Activity: Q4 2018 in Review

38 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Aevi Genomic Medicine Inc (GNMX) for Q4 2018, worth a combined $8.64M — down 45% from $15.6M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of GNMX and 2 opened new positions — a net loss of 6 holders — while 10 trimmed existing stakes and 7 added.

The largest buyer was Renaissance Technologies, adding an estimated $40.3K. The largest seller was Vanguard Group, cutting an estimated $291K.

  • 38 institutional investors held Aevi Genomic Medicine Inc (GNMX) as of Q4 2018, down from 44 in Q3 2018.
  • Funds reported $8.64M of Aevi Genomic Medicine Inc stock for Q4 2018, down 45% quarter-over-quarter.
  • 2 funds opened new Aevi Genomic Medicine Inc positions in Q4 2018 and 8 closed out, a net change of -6 holders.
  • The largest Aevi Genomic Medicine Inc buyer in Q4 2018 was Renaissance Technologies, an estimated $40.3K added.
  • The largest Aevi Genomic Medicine Inc seller in Q4 2018 was Vanguard Group, an estimated $291K sold.

Based on aggregated 13F filings for Q4 2018.